Background: Bone marrow lesions (BMLs) are a common finding in patients with osteoarthritis (OA), which are\npredictors of progression and pain related to cartilage damage in OA. The objective of the present research was to\ncompare the short-term clinical effect of intramuscular calcitonin and oral celecoxib in treating knee BMLs.\nPatients and methods: Between January 2016 and December 2018, the medical records of patients with knee\nBMLs treated by intramuscular calcitonin or oral celecoxib were reviewed. Visual analog scale (VAS) and the Western\nOntario and McMaster University Osteoarthritis Index (WOMAC) were used to assess knee pain and function,\nrespectively. BMLs were assessed by MRI scans and were scored by the modified Whole-Organ MRI Score (WORMS).\nThe safety of these two medications was also evaluated.\nResults: A total of 123 eligible patients who received calcitonin treatment..............
Loading....